Human iNKT cell activation using glycolipids with altered glycosyl groups

    公开(公告)号:AU2014317889B2

    公开(公告)日:2020-03-05

    申请号:AU2014317889

    申请日:2014-09-08

    Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

    Large scale enzymatic synthesis of oligosaccharides

    公开(公告)号:AU2019203313A1

    公开(公告)日:2019-05-30

    申请号:AU2019203313

    申请日:2019-05-10

    Abstract: Abstract A novel UDP-Gal regeneration process and its combined use with a galactosyltransferease to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

    Large scale enzymatic synthesis of oligosaccharides

    公开(公告)号:AU2018200094A1

    公开(公告)日:2018-01-25

    申请号:AU2018200094

    申请日:2018-01-05

    Abstract: Abstract A novel UDP-Gal regeneration process and its combined use with a galactosyltransferease to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

    Cancer markers and methods of use thereof

    公开(公告)号:AU2016209056A1

    公开(公告)日:2017-07-20

    申请号:AU2016209056

    申请日:2016-01-25

    Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

    Fucosidase from bacteroides and methods using the same

    公开(公告)号:AU2015267051A1

    公开(公告)日:2017-01-12

    申请号:AU2015267051

    申请日:2015-05-27

    Abstract: The present disclosure relates to an a-fucosidase having a-(1,2), a-(1,3), a-(1,4), and a-(1,6) fucosidase activity. The present disclosure also relates to the compositions comprising the α-fucosidase, and the methods of producing and using the α-fucosidase in cleaving a-(1,2), a-(1,3), a-(1,4), and/or a-(1,6)-linked fucoses in the glycoconjugates. Accordingly, the present invention provides the compositions and methods for the improved enzymatic hydrolysis of fucose in vitro. In particular, the present invention is useful for the efficient cleavage of core fucose in native glycoproteins without denaturation or functional deterioration of glycoproteins. The compositions and methods of the invention can facilitate the Fc glycoengineering of Fc fusion proteins or antibodies, such as therapeutic antibodies.

Patent Agency Ranking